Adding baseline protein biomarkers to clinical predictors does not enhance prediction of treatment response to a methotrexate strategy in early rheumatoid arthritis
Files
Publication date
2019-01-01
Authors
Teitsma, Xavier M
Jacobs, Johannes W G
De Jong, Pascal H.P.
Hazes, Johanna M.W.
Weel, Angelique E.A.M.
Welsing, Paco M J
Pethö-Schramm, Attila
Borm, Michelle E.A.
van Laar, Jacob M
Bijlsma, Johannes W J
Editors
Advisors
Supervisors
Document Type
Letter
Metadata
Show full item recordCollections
License
taverne
Abstract
Keywords
DMARDs (synthetic), methotrexate, rheumatoid arthritis, Taverne, Rheumatology, Immunology and Allergy, Immunology, General Biochemistry,Genetics and Molecular Biology, Journal Article
Citation
Teitsma, X M, Jacobs, J W G, De Jong, P H P, Hazes, J M W, Weel, A E A M, Welsing, P M J, Pethö-Schramm, A, Borm, M E A, Van Laar, J M, Bijlsma, J W J & Lafeber, F P J G 2019, 'Adding baseline protein biomarkers to clinical predictors does not enhance prediction of treatment response to a methotrexate strategy in early rheumatoid arthritis', Annals of the Rheumatic Diseases, vol. 78, no. 1, pp. 142-144. https://doi.org/10.1136/annrheumdis-2018-213767